Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

78 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Methotrexate and glucocorticoids, but not anticytokine therapy, impair the immunogenicity of a single dose of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic inflammatory arthritis.
Bugatti S, De Stefano L, Balduzzi S, Greco MI, Luvaro T, Cassaniti I, Bogliolo L, Mazzucchelli I, D'Onofrio B, di Lernia M, Mauric E, Lilleri D, Baldanti F, Manzo A, Montecucco C. Bugatti S, et al. Among authors: balduzzi s. Ann Rheum Dis. 2021 Dec;80(12):1635-1638. doi: 10.1136/annrheumdis-2021-220862. Epub 2021 Jun 25. Ann Rheum Dis. 2021. PMID: 34172502 No abstract available.
Impact of corticosteroids and immunosuppressive therapies on symptomatic SARS-CoV-2 infection in a large cohort of patients with chronic inflammatory arthritis.
Favalli EG, Bugatti S, Klersy C, Biggioggero M, Rossi S, De Lucia O, Bobbio-Pallavicini F, Murgo A, Balduzzi S, Caporali R, Montecucco C. Favalli EG, et al. Among authors: balduzzi s. Arthritis Res Ther. 2020 Dec 30;22(1):290. doi: 10.1186/s13075-020-02395-6. Arthritis Res Ther. 2020. PMID: 33380344 Free PMC article. Clinical Trial.
Reactogenicity, safety and disease flares following BNT162b2 mRNA COVID-19 vaccine in patients with chronic immune-inflammatory arthritis treated with biological and targeted synthetic disease-modifying anti-rheumatic drugs.
De Stefano L, Balduzzi S, Bogliolo L, D'Onofrio B, di Lernia M, Mauric E, Milanesi A, Brandolino F, Rocca C, Chiricolo S, Manzo A, Montecucco C, Bugatti S. De Stefano L, et al. Among authors: balduzzi s. Clin Exp Rheumatol. 2023 Mar;41(3):667-675. doi: 10.55563/clinexprheumatol/0ltj1i. Epub 2022 Sep 21. Clin Exp Rheumatol. 2023. PMID: 36135948 Free article.
Disparities in the prevalence of clinical features between systemic juvenile idiopathic arthritis and adult-onset Still's disease.
Ruscitti P, Natoli V, Consolaro A, Caorsi R, Rosina S, Giancane G, Naddei R, Di Cola I, Di Muzio C, Berardicurti O, Iacono D, Pantano I, Rozza G, Rossi S, De Stefano L, Balduzzi S, Vitale A, Caso F, Costa L, Prete M, Navarini L, Iagnocco A, Atzeni F, Guggino G, Perosa F, Cantarini L, Frediani B, Montecucco C, Ciccia F, Cipriani P, Gattorno M, Giacomelli R, Ravelli A. Ruscitti P, et al. Among authors: balduzzi s. Rheumatology (Oxford). 2022 Oct 6;61(10):4124-4129. doi: 10.1093/rheumatology/keac027. Rheumatology (Oxford). 2022. PMID: 35078234 Free PMC article.
Golimumab effectiveness in biologic inadequate responding patients with rheumatoid arthritis, psoriatic arthritis and spondyloarthritis in real-life from the Italian registry GISEA.
Iannone F, Favalli EG, Caporali R, D'Angelo S, Cantatore FP, Sarzi-Puttini P, Foti R, Conti F, Carletto A, Gremese E, Cauli A, Ramonda R, Palermo A, Epis O, Priora M, Bergossi F, Frediani B, Salaffi F, Lopalco G, Cacciapaglia F, Marchesoni A, Biggioggiero M, Bugatti S, Balduzzi S, Carriero A, Corrado A, Bongiovanni S, Benenati A, Miranda F, Fracassi E, Perra D, Ferraccioli G, Lapadula G. Iannone F, et al. Among authors: balduzzi s. Joint Bone Spine. 2021 Jan;88(1):105062. doi: 10.1016/j.jbspin.2020.07.011. Epub 2020 Aug 2. Joint Bone Spine. 2021. PMID: 32755721
78 results